ReviewAnnals of medicine and surgery (2012)2026
Beyond hemostasis: a narrative review on the multifaceted therapeutic potential of Ankaferd Blood Stopper.
Review in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Effective hemorrhage control is essential in managing trauma and surgical patients, with uncontrolled bleeding being a leading cause of mortality. Ankaferd Blood Stopper (ABS), a hemostatic agent historically used in Anatolia, has gained recognition for its ability to modulate red blood cell-fibrinogen interactions to form a stable protein network for rapid bleeding cessation. Objective: This review explores the multifaceted applications of ABS, evaluating its efficacy, safety, and potential therapeutic roles across various medical fields, including hemostasis, wound healing, antimicrobial activity, and antineoplastic effects. Methods: A comprehensive synthesis of clinical trials, case reports, and experimental studies was conducted to assess the performance and implications of ABS. This narrative review highlights its application in trauma, surgery, dental procedures, and other clinical contexts, and compares its efficacy with that of established hemostatic agents. Results: ABS demonstrates significant efficacy in achieving hemostasis in diverse clinical settings, particularly in patients with coagulopathies. Its wound healing and antimicrobial properties enhance its therapeutic versatility. Neurotoxic effects of ABS are also reported, with recent studies providing mixed evidence on nerve safety in animal models. Emerging evidence suggests potential antineoplastic effects, with studies reporting apoptosis induction in cancer cells and protective effects in experimental models. Conclusion: ABS is a promising hemostatic agent with applications in bleeding control, wound healing, and infection management. While it has shown efficacy in various clinical settings, its safety profile remains a subject of debate, with some studies confirming its biocompatibility and others reporting potential neurotoxic effects. Further large-scale human studies are needed to clarify its long-term safety and establish standardized clinical guidelines for its use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.